Promising lymphoma drug trial pulled before starting
NCT ID NCT06670105
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 26 times
Summary
This study aimed to see if the drug glofitamab could stop large B-cell lymphoma from coming back in patients who were in remission but still had tiny traces of cancer (minimal residual disease). The trial was withdrawn before enrolling any participants, so no results are available. It was designed for adults who had completed standard chemotherapy and were at high risk of relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.